posted on 2020-10-22, 22:05authored byMargherita Ortalli, Stefania Varani, Giorgia Cimato, Ruben Veronesi, Arianna Quintavalla, Marco Lombardo, Magda Monari, Claudio Trombini
Leishmaniases
are neglected diseases that can be treated with a
limited drug arsenal; the development of new molecules is therefore
a priority. Recent evidence indicates that endoperoxides, including
artemisinin and its derivatives, possess antileishmanial activity.
Here, 1,2-dioxanes were synthesized with their corresponding tetrahydropyrans
lacking the peroxide bridge, to ascertain if this group is a key pharmacophoric
requirement for the antileishmanial bioactivity. Newly synthesized
compounds were examined in vitro, and their mechanism
of action was preliminarily investigated. Three endoperoxides and
their corresponding tetrahydropyrans effectively inhibited the growth
of Leishmania donovani promastigotes
and amastigotes, and iron did not play a significant role in their
activation. Further, reactive oxygen species were produced in both
endoperoxide- and tetrahydropyran-treated promastigotes. In conclusion,
the peroxide group proved not to be crucial for the antileishmanial
bioactivity of endoperoxides, under the tested conditions. Our findings
reveal the potential of both 1,2-dioxanes and tetrahydropyrans as
lead compounds for novel therapies against Leishmania.